Insights

A Window of Opportunity: The Promise of Digital Health in Pharma

Pete Masloski and Maurice Solomon


Download

Today’s digital health solutions can address many of pharma’s most vexing problems, but unfortunately, too many pharma companies haven’t yet realized digital health’s full potential. The industry has learned a lot from its experimentation with digital health, and several trends suggest that digital health overall is reaching a critical inflection point. Increased competition from tech players and startups, and growing support for a range of specific and tangible use cases, also suggest that pharma is getting close to realizing the payoff from digital health.

According to ZS’s digital health team’s research, the potential impact of digital health for pharma represents an eye-opening $100 billion opportunity. Read our article to find out how to capitalize on it.

About the Experts





Pete Masloski is a managing principal in ZS’s Evanston, Ill., office and leads ZS’s digital and connected health practice. For over 20 years, Pete has focused on helping clients improve the effectiveness of their marketing and sales efforts around the globe. Pete has authored numerous blogs, articles and white papers on a variety of topics including the impact of healthcare reform on the medical device industry, medical technology industry trends, digital and connected health, patient centricity, mergers and acquisitions, organization design and sales force effectiveness.





Maurice Solomon is an associate principal in ZS’s Los Angeles office, and is a senior leader in the firm’s digital and connected health practice. Maurice has over a decade of strategy, corporate development and solution design experience in the digital health space, both as a consultant and in the industry overseeing a portfolio of digital solutions.